'Very Impressive' Survival With Combo in First-Line Prostate Cancer Study

(MedPage Today) — SAN FRANCISCO — The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…

Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/120096

Author :

Publish date : 2026-02-27 22:43:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

‘Very Impressive’ Survival With Combo in First-Line Prostate Cancer Study

More Parents Say ‘No’ to Vitamin K Shots for Newborns

I woke up from an operation in agony and the pain never went away

Related Posts

Autism Panel Targets RFK Jr.’s Agenda

HPV Self-Testing in Primary Care Boosts Cervical Cancer Screening

It Was a Rough Match Day for Family Medicine, IMGs

Study Warns on High-Risk Group After Stool-Based Colon Cancer Screening

Match Day 2026: Is Family Medicine Half-Full or Half-Empty?

Victoria Pilots PA Program for Harm Reduction Workers

Autism Panel Targets RFK Jr.’s Agenda

HPV Self-Testing in Primary Care Boosts Cervical Cancer Screening

It Was a Rough Match Day for Family Medicine, IMGs

Study Warns on High-Risk Group After Stool-Based Colon Cancer Screening

Match Day 2026: Is Family Medicine Half-Full or Half-Empty?

Victoria Pilots PA Program for Harm Reduction Workers

Match Day Joy: Today Is the Day for Thousands of Students

Next-Gen Nerve Stimulator Approved for Obstructive Sleep Apnea

Categories

Archives